Understanding the Root Causes of Chronic Anxiety

Share this post:

LinkedIn
Facebook
X
Reddit
WhatsApp
Print

Chronic anxiety usually comes from a mix of inherited risk, brain chemistry, stress exposure, learned fear patterns and past trauma. It does not come from one single source. Your symptoms may reflect how your genes, nervous system and life experiences have interacted over time.

If you live with chronic anxiety, your brain and body may stay too ready for danger even during ordinary situations. That state can build gradually. It can start with inherited sensitivity, repeated life stress, family instability, poor sleep, health problems, substance use or traumatic events. In many people, several of these factors overlap and reinforce each other.

This is why the causes of anxiety can feel hard to pin down. You may look for one trigger and miss the wider pattern. A stressful job may be part of it, but so may a family history of anxiety. A recent life event may have pushed symptoms higher, but your nervous system may already have been more reactive for years. Chronic anxiety often reflects a system that has been shaped by biology and experience at the same time.

The genetic and biological factors

Genetics can raise your risk for anxiety. If anxiety or related mental health conditions run in your family, your own nervous system may be more likely to react strongly to stress. This does not mean you are locked into an anxiety disorder. It means you may have a higher baseline vulnerability that can become more visible under pressure.

Brain chemistry also plays a role. Anxiety involves changes in neurotransmitters and hormones that affect alertness, fear, mood and recovery. These include norepinephrine, serotonin, dopamine and GABA. When these systems are dysregulated, your brain may become more reactive to uncertainty, more likely to scan for danger and slower to settle after stress.

The amygdala is another part of the picture. This region helps detect threat and signal fear. People with anxiety disorders often show increased amygdala activity when they face anxiety related cues. If this system is overactive, your brain may assign high threat value to situations that other people can process with less alarm.

Your stress response system can also stay activated for too long. When the body perceives danger, the sympathetic nervous system and stress hormones help prepare you for action. Heart rate rises, breathing quickens and muscles tense. That response is useful in short bursts. Chronic stress and anxiety can strain that system and keep your body in a prolonged state of activation.

Biology also includes physical health. Certain medical conditions, medication effects, stimulant use, poor sleep and hormone changes can increase anxiety symptoms or lower your threshold for stress. This does not mean every case of anxiety has a medical cause, but it does mean the body and brain are tightly linked in the development of symptoms.

Temperament matters too. Some people are born more sensitive to stimulation, uncertainty or social evaluation. A child who startles easily, worries often or reacts strongly to change may carry that pattern into adult life. With enough support, that sensitivity can be managed well. Under prolonged stress, it can become part of chronic anxiety.

Environmental triggers and modern chronic stress

Environmental stress can push an already sensitive nervous system into a more persistent anxiety pattern. This includes work pressure, financial strain, unstable housing, conflict at home, caregiving demands, illness, grief, bullying, relationship problems and repeated uncertainty. When stressors pile up, your body may stop returning fully to baseline.

Modern life can keep that pressure running for long periods. Constant demands, poor sleep, irregular schedules, social comparison, overstimulation and limited recovery time can all increase baseline tension. Your brain may start treating ordinary daily life as a field of ongoing threat. Over time, this can change how quickly you become anxious and how long it takes you to calm down.

Family environment also shapes anxiety risk. If you grew up around high stress, unpredictability, criticism or anxious caregiving, your nervous system may have learned that vigilance is necessary. Children often absorb threat patterns from the home even when nothing dramatic happens. Repeated exposure to tension can teach the brain to expect danger early and often.

Life events can act as turning points. A breakup, job loss, move, illness, injury, accident or period of social isolation can trigger symptoms that then keep going. In some cases the event is obvious. In others, anxiety rises after months of accumulated strain rather than one clear incident. Both pathways are common.

Stress can also change behavior in ways that keep anxiety alive. You may start sleeping poorly, relying on caffeine, avoiding hard tasks, withdrawing from people or checking your body and surroundings more often. These habits can strengthen the feeling that danger is always near. What begins as a reaction to stress can become a daily pattern that feeds itself.

Chronic stress does not affect everyone in the same way. Two people can go through similar pressure and respond differently. Genetics, past experiences, health status, coping skills and social support all affect the outcome. This is another reason chronic anxiety usually reflects several causes interacting at once rather than a single explanation.

How past trauma shapes your current nervous system

Past trauma can leave the nervous system in a lasting state of threat readiness. A traumatic event may be a single incident such as an assault, accident or medical emergency. It may also involve prolonged exposure to fear, neglect, abuse, coercion or instability. Trauma can change how your brain predicts danger and how your body reacts long after the event has passed.

After trauma, the brain may become more sensitive to cues that resemble earlier danger. A sound, smell, setting, body sensation or social dynamic can trigger alarm even if the current situation is safe. This is because trauma affects fear learning, memory and the body’s automatic defense systems. The reaction can be rapid and physical before you have time to think it through.

Trauma can also shrink your sense of safety in daily life. You may become hypervigilant, easily startled, tense, irritable or emotionally flooded. Sleep may become lighter. Crowds may feel threatening. Quiet moments may feel uncomfortable because your system expects danger when it lets its guard down. These are not random reactions. They reflect a nervous system shaped by prior survival demands.

Some trauma related anxiety is easy to connect to the past. Some is harder to recognize. You may think of yourself as simply anxious, overreactive or bad at coping when your body is actually carrying old fear patterns. This can happen after childhood adversity, emotionally unpredictable homes or long periods where you had to stay alert to stay safe. Trauma does not have to fit one dramatic stereotype to leave a deep imprint on the nervous system.

This is why symptom control alone may feel incomplete for some people. Breathing techniques, sleep changes and therapy skills can help a lot. At the same time, trauma related anxiety often involves fear pathways that were built under intense conditions and reinforced across time. Those deeper patterns may need approaches that address memory, body based alarm and the brain’s learned threat responses.

Healing often begins when you can see the pattern clearly. Chronic anxiety may reflect inherited sensitivity. It may reflect current stress. It may reflect trauma that trained your nervous system to stay prepared for danger. In many cases it reflects all three. Once you identify that wider picture, treatment choices tend to become more grounded and more specific to your actual symptoms.

As you think about anxiety at the level of genetics, stress and trauma stored in the nervous system, we at Rose Hill Life Sciences remain committed to studying therapies that address root causes instead of simply masking daily symptoms. We are a psychedelic research organization specializing in the production and research of Psilocybe cubensis, operating at the intersection of science and therapeutic integration, and based in Massachusetts.

Disclaimer: The information in this article is for educational and informational purposes only and does not constitute medical advice.

You May Also Like

Adam Goodman

Advisor

Adam is a seasoned entrepreneur with a wealth of experience in spearheading real estate development and management endeavors. His focus primarily lies in land development, where he orchestrates the intricate tapestry of planning and zoning entitlements, while meticulously overseeing all facets of engineering and architectural design, leasing, construction, and financing.

With a national reach spanning 23 states and encompassing over 250 properties, totaling more than 6 million square feet, Adam’s proficiency in navigating the complexities of the industry is evident.

Beyond real estate, Adam’s endeavors extend into the realm of alternative investments, boasting successful ventures in healthcare, professional sports franchises, financial services, diverse agricultural platforms, and the stewardship of local restaurants.

 

Rotem Petranker, PhD, Psychology

Psychedelic Researcher

Rotem Petranker is a psychedelics researcher with a particular emphasis on microdosing, therapy, research methods and research ethics. He earned his BSc from the University of Toronto, his Master’s degree from York University, and his PhD from McMaster University.

As part of my research, I have gained extensive expertise in navigating the regulatory landscapes of Health Canada and the FDA and a strong background in designing rigorous clinical trial research methodologies. 

I founded the Canadian Centre for Psychedelic Science in 2018, established the Psychedelic Science Research Program at the University of Toronto in 2019, and, more recently, ran the largest clinical trial to date on the effectiveness of microdosing psilocybin for Major Depressive Disorders. I have published many papers on microdosing, including some of the largest samples in the literature and some that have set standards for performing psychedelic research.

Kevin Bourke

Chief Commercial Officer

Kevin Bourke is a dynamic executive and strategic planner whose career spans over two decades of crafting and elevating world-class Jamaican brands and transformational experiences on the global stage. With a keen understanding of culture, identity, and international markets, he has played a pivotal role in shaping some of Jamaica’s most iconic names — including Appleton Estate Rum, Chris Blackwell’s Rum, and Usain Bolt’s Tracks & Records — bringing them from local roots to international acclaim. His leadership and vision have also been instrumental in major cultural movements such as Fiction and the internationally recognized TmrwTday Wellness Festival.

An innovator at heart, Mr. Bourke seamlessly blends brand strategy with deep cultural resonance. His ability to connect with diverse audiences has established these brands not only as commercial successes but as symbolic ambassadors of Jamaican excellence, fortifying the island’s influence in beverage, music, lifestyle, and experiential sectors.

In recent years, Kevin has steered his strategic acumen toward the cutting-edge psilocybin and wellness industry, becoming a co-founder and Chief Marketing and Branding Officer of Rose Hill, Jamaica’s leading cultivator, exporter, and innovator of psilocybin products and experiences. Through ventures like ONE Retreats, he has helped craft safe, guided psychedelic-assisted healing programs that attract participants from around the world seeking deep personal transformation, including military veterans and international wellness seekers.

Kevin’s impact extends beyond business into industry shaping and policy, as he sits on the Jamaica Psilocybin Mushroom Industry Technical Committee (under the Bureau of Standards) — a pivotal body that is formalizing guidelines and regulatory standards for the emerging legal psilocybin sector in Jamaica. His presence on this committee underscores his leadership role in ensuring the industry’s integrity, safety, and sustainable growth.

Highly regarded for his extensive network throughout Jamaica and internationally, Kevin remains passionately committed to advancing ethical, high-integrity product development and customer-centric experiences at every level. His dedication is driven not only by professional achievement but by a deep vision for human well-being, cultural celebration, and the global evolution of plant-based healing.

Jama Pitman

Regulatory Strategy

Jama Pitman is a seasoned biopharmaceutical executive with extensive expertise in global drug development and commercialization. With over two decades of experience, she has contributed to the development of groundbreaking therapies across oncology, rare diseases, and antivirals. As a strategic leader, she has successfully transitioned companies from private to public markets, navigated complex M&A transactions, and driven innovative drug approvals.

Jama has held executive roles in leading organizations, including Deciphera Pharmaceuticals, where she played a pivotal role in scaling operations from a small, privately held biotech company to a global, multi-product company acquired for $2.4 billion. She brings exceptional skills in regulatory affairs, portfolio management, quality assurance, and clinical operations, longside a proven track record of fostering inclusivity and mentorship within her teams.

Currently, as the founder of JP BioPharma Consulting, Jama advises biopharma and tech companies on accelerating drug development and achieving corporate goals. Her collaborative and forward-thinking approach aligns seamlessly with Rose Hill’s mission to advance transformative therapies in mental health and beyond.

Education: B.Sc. in Microbiology, University of New Hampshire.

Notable Achievements: Contributed to the development of multiple FDA-approved therapies, including QINLOCK® for gastrointestinal stromal tumors.

Domenic Suppa

Chief Operating Officer

Domenic is co-founder and the Operations Chief of Rose Hill Health Holdings.

He has been working as a Cannabis technology and operations veteran with more than 11 years’ experience as a senior executive in an operationally complex, and highly regulated industry.

His introduction and entrance into the Cannabis sector started in 2010 with a seed investment into a Denver-based vertically integrated cannabis company called, Evolab. He served as C.O.O. for 5 years from 2013-2018, through the eventual acquisition by Harvest Health and Recreation (HARV: CSE).

Domenic moved on to be acting COO of the manufacturing division for Supreme Cannabis (CSE: FIRE) and supported the acquisition of BLISSCO (CSE: BLISS, a BC-based cannabis manufacturer). Domenic has worked with high-profile national cannabis brands including KKE, and Monogram, and retail brands in MA Native Sun, Terps, and Tilt. Domenic is a proven leader and team builder; his previous experiences have all been with early-stage and growth equity enterprises.

He has refined and evolved his leadership roles, including his team-building skills. He is a value creator. Domenic is a firm believer in training and continuous development. He excels in employing practices, tools, and methodologies designed to achieve maximum process efficiency while minimizing waste and delays.

 

Burton J. Tabaac

Clinical Development

Dr. Burton J. Tabaac, MD, FAHA, brings a wealth of expertise in neurology and stroke rehabilitation to Rose Hill. As an Associate Professor and Section Chief of Neurology at The University of Nevada’s Reno School of Medicine, and Medical Director of Stroke at Carson Tahoe Health, Dr. Tabaac has been at the forefront of innovative neurological treatments.

A graduate of the prestigious cerebrovascular neurology fellowship program at The Johns Hopkins University Hospital, Dr. Tabaac’s accolades include being a three-time recipient of The Arnold P. Gold Foundation’s Humanism and Excellence in Teaching Award and induction into the Alpha Omega Alpha Honor Medical Society.

He recently published an eight-part paper in the American Journal of Therapeutics reviewing psychedelics as therapeutics for primary care clinicians. Dr. Tabaac’s groundbreaking research focuses on the application of psychedelics in brain injury and stroke rehabilitation.

Dr. Tabaac was recently appointed by the Governor of Nevada to serve as a member of the state’s Psychedelic Medicines Working Group, which provides expertise and testimony relating to the therapeutic use of entheogens.

As the host of The Zero Hour Podcast, he engages with leading experts in psychedelic research. His commitment to advancing the field was further highlighted in his 2022 TEDx talk at UCLA, “Mental Health Meets Psychedelics.”

“Joining Rose Hill’s advisory team presents an exciting opportunity to further explore the potential of psilocybin in neurological recovery,” said Dr. Tabaac.

“The company’s commitment to ethical cultivation and research aligns perfectly with my vision for advancing patient care through innovative therapies. I’m eager to bring my expertise to Rose Hill and contribute to the evolving landscape of psychedelic medicine.”

Charles Lazarus

Chief Executive Office

Mr. Lazarus boasts over 16 years of extensive expertise in psilocybin and cannabis, focusing on genetic development, cultivation, extraction, and operations logistics. Notably, he recently achieved a milestone by cultivating and delivering the largest legal shipment of premium psilocybin globally.

As an accomplished owner/operator, Mr. Lazarus has successfully managed multiple farming and harvesting businesses, earning commendations for his unwavering commitment to quality and impressive output volumes. Since 2015, he has been actively involved in producing proprietary psilocybin genetics and cultivation solutions tailored for the Jamaican market and large research and development clients.

His contributions span various aspects, including genetic development, cultivation, extraction, harvest, and logistics. Additionally, Mr. Lazarus owned and operated Island Fresh Ltd., a venture that played a pivotal role in exporting fresh fruit, ground provisions, and promoting brand Jamaica to the English market. Under his leadership, Island Fresh Ltd. achieved the highest volume from Jamaica for three consecutive years.

Mr. Lazarus’s extensive experience also includes serving as the Harvest Manager for cannabis grow operations in California from 2013 to 2017, further solidifying his comprehensive knowledge in the cannabis industry.